MedTrace Logo

Non-Invasive Determination of Fetal Chromosome Abnormalities

NCT00891852 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2009-05-01

No results posted yet for this study

Summary

The overall significance of this study is to develop a laboratory developed test (LDT) to use a new marker in the maternal blood to better identify pregnancies that have a child with a chromosome abnormality such as Down syndrome (trisomy 21), Edward's syndrome (trisomy 18), Patau syndrome (trisomy 13), Klinefelter syndrome, (47, XXY), and other chromosome abnormalities. Accomplishing that task would reduce the need for invasive amniocentesis and CVS procedures.

Conditions

  • Down Syndrome (Trisomy 21)
  • Edward's Syndrome (Trisomy 18)
  • Patau Syndrome (Trisomy 13)
  • Klinefelter Syndrome (47, XXY)
  • and Other Chromosome
  • Abnormalities.

Sponsors & Collaborators

  • Lenetix Medical Screening Laboratory

    lead INDUSTRY

Principal Investigators

  • Stephen A Brown, MD · Lenetix, Inc.

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00891852 on ClinicalTrials.gov